IDEAS home Printed from https://ideas.repec.org/f/phe632.html
   My authors  Follow this author

Manuel Hermosilla

Personal Details

First Name:Manuel
Middle Name:
Last Name:Hermosilla
Suffix:
RePEc Short-ID:phe632
[This author has chosen not to make the email address public]

Affiliation

Carey Business School
Johns Hopkins University

Baltimore, Maryland (United States)
http://www.carey.jhu.edu/
RePEc:edi:bsjhuus (more details at EDIRC)

Research output

as
Jump to: Working papers Articles Chapters

Working papers

  1. David Dranove & Craig Garthwaite & Manuel I. Hermosilla, 2020. "Expected Profits and The Scientific Novelty of Innovation," NBER Working Papers 27093, National Bureau of Economic Research, Inc.
  2. Manuel I. Hermosilla & Jorge A. Lemus, 2017. "Therapeutic Translation of Genomic Science: Opportunities and limitations of GWAS," NBER Working Papers 23989, National Bureau of Economic Research, Inc.
  3. Hermosilla, Manuel & Gutierrez-Navratil, Fernanda & Prieto-Rodriguez, Juan, 2017. "Can Emerging Markets Tilt Global Product Design? Impacts of Chinese Colorism on Hollywood Castings," MPRA Paper 82040, University Library of Munich, Germany.
  4. David Dranove & Craig Garthwaite & Manuel Hermosilla, 2014. "Pharmaceutical Profits and the Social Value of Innovation," NBER Working Papers 20212, National Bureau of Economic Research, Inc.
  5. Eduardo Engel & Ronald Fischer & Alexander Galetovic & Manuel Hermosilla, 2009. "Renegociación de concesiones en Chile," Documentos de Trabajo 262, Centro de Economía Aplicada, Universidad de Chile.

Articles

  1. Ching, Andrew T. & Hermosilla, Manuel & Liu, Qiang, 2019. "Structural Models of the Prescription Drug Market," Foundations and Trends(R) in Marketing, now publishers, vol. 13(1), pages 1-1–76, December.
  2. Hermosilla, Manuel & Wu, Yufei, 2018. "Market size and innovation: The intermediary role of technology licensing," Research Policy, Elsevier, vol. 47(5), pages 980-991.

Chapters

  1. Manuel Hermosilla & Jorge Lemus, 2018. "Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 21-52, National Bureau of Economic Research, Inc.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Working papers

  1. David Dranove & Craig Garthwaite & Manuel I. Hermosilla, 2020. "Expected Profits and The Scientific Novelty of Innovation," NBER Working Papers 27093, National Bureau of Economic Research, Inc.

    Cited by:

    1. Dranove, David & Garthwaite, Craig & Heard, Christopher & Wu, Bingxiao, 2022. "The economics of medical procedure innovation," Journal of Health Economics, Elsevier, vol. 81(C).
    2. Matthew T. Knowles, 2022. "How access to addictive drugs affects the supply of substance abuse treatment: Evidence from Medicare Part D," Health Economics, John Wiley & Sons, Ltd., vol. 31(8), pages 1649-1675, August.
    3. Jan Malek & Melissa Newham & Jo Seldeslachts & Reinhilde Veugelers, 2024. "Acquiring R&D projects: who, when, and what? Evidence from antidiabetic drug development," Working Papers of Department of Management, Strategy and Innovation, Leuven 735739, KU Leuven, Faculty of Economics and Business (FEB), Department of Management, Strategy and Innovation, Leuven.
    4. Beth Woods & James Lomas & Mark Sculpher & Helen Weatherly & Karl Claxton, 2024. "Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required," Health Economics, John Wiley & Sons, Ltd., vol. 33(4), pages 804-819, April.
    5. Michael D. Frakes & Melissa F. Wasserman, 2020. "Investing in Ex Ante Regulation: Evidence from Pharmaceutical Patent Examination," NBER Working Papers 27579, National Bureau of Economic Research, Inc.
    6. Leila Agha & Soomi Kim & Danielle Li, 2020. "Insurance Design and Pharmaceutical Innovation," NBER Working Papers 27563, National Bureau of Economic Research, Inc.

  2. Manuel I. Hermosilla & Jorge A. Lemus, 2017. "Therapeutic Translation of Genomic Science: Opportunities and limitations of GWAS," NBER Working Papers 23989, National Bureau of Economic Research, Inc.

    Cited by:

    1. Veenstra David L. & Mandelblatt Jeanne & Neumann Peter & Basu Anirban & Peterson Josh F. & Ramsey Scott D., 2020. "Health Economics Tools and Precision Medicine: Opportunities and Challenges," Forum for Health Economics & Policy, De Gruyter, vol. 23(1), pages 1-14, June.
    2. Manuel Hermosilla, 2021. "Rushed Innovation: Evidence from Drug Licensing," Management Science, INFORMS, vol. 67(1), pages 257-278, January.

  3. Hermosilla, Manuel & Gutierrez-Navratil, Fernanda & Prieto-Rodriguez, Juan, 2017. "Can Emerging Markets Tilt Global Product Design? Impacts of Chinese Colorism on Hollywood Castings," MPRA Paper 82040, University Library of Munich, Germany.

    Cited by:

    1. Yu Hu & Yonggui Wang, 2020. "Marketing research in China during the 40-year reform and opening," Frontiers of Business Research in China, Springer, vol. 14(1), pages 1-29, December.
    2. Venkatesh Shankar & Unnati Narang, 2020. "Emerging market innovations: unique and differential drivers, practitioner implications, and research agenda," Journal of the Academy of Marketing Science, Springer, vol. 48(5), pages 1030-1052, September.
    3. Verdiana Giannetti & Jieke Chen, 2023. "An investigation of the impact of Black male and female actors on US movies’ box-office across countries," Marketing Letters, Springer, vol. 34(2), pages 269-291, June.
    4. Venkatesh Shankar & Sohil Parsana, 2022. "An overview and empirical comparison of natural language processing (NLP) models and an introduction to and empirical application of autoencoder models in marketing," Journal of the Academy of Marketing Science, Springer, vol. 50(6), pages 1324-1350, November.
    5. Tin Cheuk Leung & Shi Qi, 2023. "Globalization and the rise of action movies in hollywood," Journal of Cultural Economics, Springer;The Association for Cultural Economics International, vol. 47(1), pages 31-69, March.
    6. Konrad Adler & Simon Fuchs, 2022. "Globalization and Heterogeneity: Evidence from Hollywood," FRB Atlanta Working Paper 2022-14, Federal Reserve Bank of Atlanta.
    7. Jordi McKenzie, 2023. "The economics of movies (revisited): A survey of recent literature," Journal of Economic Surveys, Wiley Blackwell, vol. 37(2), pages 480-525, April.
    8. Xi, Chen & Xie, Wei & Chen, Xiaoguang & He, Pan, 2023. "Weather shocks and movie recreation demand in China," Energy Economics, Elsevier, vol. 127(PB).
    9. Xiaolin Li & Chenxi Liao & Ying Xie, 2021. "Digital Piracy, Creative Productivity, and Customer Care Effort: Evidence from the Digital Publishing Industry," Marketing Science, INFORMS, vol. 40(4), pages 685-707, July.

  4. David Dranove & Craig Garthwaite & Manuel Hermosilla, 2014. "Pharmaceutical Profits and the Social Value of Innovation," NBER Working Papers 20212, National Bureau of Economic Research, Inc.

    Cited by:

    1. Hermosilla, Manuel & Wu, Yufei, 2018. "Market size and innovation: The intermediary role of technology licensing," Research Policy, Elsevier, vol. 47(5), pages 980-991.
    2. Dranove, David & Garthwaite, Craig & Heard, Christopher & Wu, Bingxiao, 2022. "The economics of medical procedure innovation," Journal of Health Economics, Elsevier, vol. 81(C).
    3. Colleen Carey, 2017. "Technological Change and Risk Adjustment: Benefit Design Incentives in Medicare Part D," American Economic Journal: Economic Policy, American Economic Association, vol. 9(1), pages 38-73, February.
    4. Margaret K. Kyle, 2019. "The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals," NBER Chapters, in: Innovation Policy and the Economy, Volume 20, pages 95-123, National Bureau of Economic Research, Inc.
    5. Barton H. Hamilton & Andrés Hincapié & Robert A. Miller & Nicholas W. Papageorge, 2021. "Innovation And Diffusion Of Medical Treatment," International Economic Review, Department of Economics, University of Pennsylvania and Osaka University Institute of Social and Economic Research Association, vol. 62(3), pages 953-1009, August.
    6. Manuel I. Hermosilla & Jorge A. Lemus, 2017. "Therapeutic Translation of Genomic Science: Opportunities and limitations of GWAS," NBER Working Papers 23989, National Bureau of Economic Research, Inc.
    7. Matthew T. Knowles, 2022. "How access to addictive drugs affects the supply of substance abuse treatment: Evidence from Medicare Part D," Health Economics, John Wiley & Sons, Ltd., vol. 31(8), pages 1649-1675, August.
    8. Fabian Gaessler & Stefan Wagner, 2022. "Patents, Data Exclusivity, and the Development of New Drugs," The Review of Economics and Statistics, MIT Press, vol. 104(3), pages 571-586, May.
    9. Matthew J. Higgins & Xin Yan & Chirantan Chatterjee, 2018. "Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling," NBER Working Papers 24957, National Bureau of Economic Research, Inc.
    10. Mark Duggan & Craig Garthwaite & Aparajita Goyal, 2016. "The Market Impacts of Pharmaceutical Product Patents in Developing Countries: Evidence from India," American Economic Review, American Economic Association, vol. 106(1), pages 99-135, January.
    11. Manuel Hermosilla, 2021. "Rushed Innovation: Evidence from Drug Licensing," Management Science, INFORMS, vol. 67(1), pages 257-278, January.
    12. Ruchir Agarwal & Patrick Gaulé, 2021. "What Drives Innovation? Lessons from COVID-19 R&D," IMF Working Papers 2021/048, International Monetary Fund.
    13. Caroline Savage Bennette & Anirban Basu & Scott D. Ramsey & Zachary Helms & Peter B. Bach, 2019. "Health Returns to Pharmaceutical Innovation in the Market for Oral Chemotherapy in Response to Insurance Coverage Expansion," American Journal of Health Economics, MIT Press, vol. 5(3), pages 360-375, Summer.
    14. Sanzenbacher, Geoffrey T. & Wettstein, Gal, 2020. "Drug insurance and the strategic behavior of drug manufacturers: Evergreening and generic entry after Medicare Part D," Journal of Health Economics, Elsevier, vol. 72(C).
    15. David Dranove & Craig Garthwaite & Manuel I. Hermosilla, 2020. "Expected Profits and The Scientific Novelty of Innovation," NBER Working Papers 27093, National Bureau of Economic Research, Inc.
    16. Jillian Chown & David Dranove & Craig Garthwaite & Jordan Keener, 2019. "The Opportunities and Limitations of Monopsony Power in Healthcare: Evidence from the United States and Canada," NBER Working Papers 26122, National Bureau of Economic Research, Inc.

  5. Eduardo Engel & Ronald Fischer & Alexander Galetovic & Manuel Hermosilla, 2009. "Renegociación de concesiones en Chile," Documentos de Trabajo 262, Centro de Economía Aplicada, Universidad de Chile.

    Cited by:

    1. Alexander Moore & Stéphane Straub & Jean-Jacques Dethier, 2014. "Regulation, renegotiation and capital structure: theory and evidence from Latin American transport concessions," Journal of Regulatory Economics, Springer, vol. 45(2), pages 209-232, April.
    2. Eduardo Engel & Ronald Fischer & Alexander Galetovic, 2015. "Soft Budgets and Renegotiations in Public-Private Partnerships:Theory and Evidence," Working Papers wp408, University of Chile, Department of Economics.
    3. Daniel Danau & Annalisa Vinella, 2015. "Public-Private Contracting under Limited Commitment," Post-Print halshs-00939872, HAL.
    4. Engel,Eduardo & Galetovic Potsch,Alexander, 2014. "Urban transport : can public-private partnerships work ?," Policy Research Working Paper Series 6873, The World Bank.
    5. Fischer, Ronald & Valenzuela, Patricio, 2013. "Financial Openness, Market Structure and Private Credit: An Empirical Investigation," Working Papers 13-26, University of Pennsylvania, Wharton School, Weiss Center.
    6. Sofia Bauducco & Alexandre Janiak, 2012. "Minimum wages strike back: the effects on capital and labor demands in a large-firm framework," Documentos de Trabajo 287, Centro de Economía Aplicada, Universidad de Chile.
    7. Felipe Balmaceda, 2013. "On the Optimality of One-size-fits-all Contracts: The Limited Liability Case," Working Papers 39, Facultad de Economía y Empresa, Universidad Diego Portales.
    8. Engel, Eduardo & Fischer, Ronald D. & Galetovic, Alexander, 2024. "The company you keep: Renegotiations and adverse selection in transportation infrastructure," Economics of Transportation, Elsevier, vol. 38(C).
    9. Gabriel Castelblanco & Jose Guevara & Harrison Mesa & Diego Flores, 2020. "Risk Allocation in Unsolicited and Solicited Road Public-Private Partnerships: Sustainability and Management Implications," Sustainability, MDPI, vol. 12(11), pages 1-28, June.
    10. Eduardo Engel & Ronald Fischer & Alexander Galetovic, 2009. "Soft Budgets and Renegotiations in Public-Private Partnerships," Cowles Foundation Discussion Papers 1723, Cowles Foundation for Research in Economics, Yale University.
    11. Balmaceda, Felipe & Escobar, Juan F., 2017. "Trust in cohesive communities," Journal of Economic Theory, Elsevier, vol. 170(C), pages 289-318.
    12. Juan F. Escobar & Juuso Toikka, 2013. "Efficiency in Games With Markovian Private Information," Econometrica, Econometric Society, vol. 81(5), pages 1887-1934, September.
    13. Diego Huerta & Ronald Fischer & Patricio Valenzuela, 2015. "Inequality and Private Credit," Documentos de Trabajo 316, Centro de Economía Aplicada, Universidad de Chile.
    14. Engel, Eduardo M.R:A. & Fischer, Ronald & Galetovic, Alexander, 2019. "Soft budgets and endogenous renegotiations in transport PPPs: An equilibrium analysis," Economics of Transportation, Elsevier, vol. 17(C), pages 40-50.
    15. Andreasen, Eugenia & Valenzuela, Patricio, 2016. "Financial openness, domestic financial development and credit ratings," Finance Research Letters, Elsevier, vol. 16(C), pages 11-18.
    16. Antonio Romero-Medina & Matteo Triossi, 2012. "Neutral Mergers Between Bilateral Markets," Documentos de Trabajo 292, Centro de Economía Aplicada, Universidad de Chile.
    17. Felipe Balmaceda & Juan F. Escobar, 2012. "Self Governance in Social Networks of Information Transmission," Documentos de Trabajo 290, Centro de Economía Aplicada, Universidad de Chile.
    18. Elton Dusha, 2015. "Reputational Concerns in Directed Search Markets with Adverse Selection," Documentos de Trabajo 318, Centro de Economía Aplicada, Universidad de Chile.

Articles

  1. Ching, Andrew T. & Hermosilla, Manuel & Liu, Qiang, 2019. "Structural Models of the Prescription Drug Market," Foundations and Trends(R) in Marketing, now publishers, vol. 13(1), pages 1-1–76, December.

    Cited by:

    1. Shervin Shahrokhi Tehrani & Andrew T. Ching, 2024. "A Heuristic Approach to Explore: The Value of Perfect Information," Management Science, INFORMS, vol. 70(5), pages 3200-3224, May.
    2. Dubois, Pierre & Lasio, Laura, 2014. "Identifying Industry Margins with Unobserved Price Constraints: Structural Estimation on Pharmaceuticals," CEPR Discussion Papers 9881, C.E.P.R. Discussion Papers.
    3. Callejas, Jerónimo & Mohapatra, Debi Prasad, 2021. "Welfare effects of public procurement of medicines: Evidence from Ecuador," International Journal of Industrial Organization, Elsevier, vol. 75(C).
    4. McKibbin, Rebecca, 2023. "The effect of RCTs on drug demand: Evidence from off-label cancer drugs," Journal of Health Economics, Elsevier, vol. 90(C).

  2. Hermosilla, Manuel & Wu, Yufei, 2018. "Market size and innovation: The intermediary role of technology licensing," Research Policy, Elsevier, vol. 47(5), pages 980-991.

    Cited by:

    1. Mayank Aggarwal & Anindya Chakrabarti & Chirantan Chatterjee & Matthew J. Higgins, 2021. "Research and Market Structure: Evidence from an Antibiotic-Resistant Pathogenic Outbreak," NBER Working Papers 28840, National Bureau of Economic Research, Inc.
    2. Matthew J. Higgins & Xin Yan & Chirantan Chatterjee, 2018. "Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling," NBER Working Papers 24957, National Bureau of Economic Research, Inc.
    3. Luca Sandrini, 2020. "Innovation, Competition, and Incomplete Adoption of a Superior Technology," "Marco Fanno" Working Papers 0251, Dipartimento di Scienze Economiche "Marco Fanno".
    4. Manuel Hermosilla, 2021. "Rushed Innovation: Evidence from Drug Licensing," Management Science, INFORMS, vol. 67(1), pages 257-278, January.
    5. Pei-Hsuan Tsai & Chih-Jou Chen & Ho-Chin Yang, 2021. "Using Porter’s Diamond Model to Assess the Competitiveness of Taiwan’s Solar Photovoltaic Industry," SAGE Open, , vol. 11(1), pages 21582440209, January.
    6. Cai-Xia Song & Cui-Xia Qiao, 2023. "Technology Importation, Institutional Environment and Industrial Upgrading: Evidence from China," Journal of Economics / Ekonomicky casopis, Institute of Economic Research, Slovak Academy of Sciences, vol. 71(1), pages 23-45, January.
    7. Zufeng Shang & Fenglai Wang & Xu Yang, 2022. "The Efficiency of the Chinese Prefabricated Building Industry and Its Influencing Factors: An Empirical Study," Sustainability, MDPI, vol. 14(17), pages 1-25, August.
    8. Moreira, Solon & Klueter, Thomas Maximilian & Asija, Aman, 2023. "Market for technology 2.0? Reassessing the role of complementary assets on licensing decisions," Research Policy, Elsevier, vol. 52(7).
    9. Michaela Kotkova Striteska & Viktor Prokop, 2020. "Dynamic Innovation Strategy Model in Practice of Innovation Leaders and Followers in CEE Countries—A Prerequisite for Building Innovative Ecosystems," Sustainability, MDPI, vol. 12(9), pages 1-20, May.
    10. Shiying Hou & Liangrong Song, 2021. "Market Integration and Regional Green Total Factor Productivity: Evidence from China’s Province-Level Data," Sustainability, MDPI, vol. 13(2), pages 1-19, January.

Chapters

  1. Manuel Hermosilla & Jorge Lemus, 2018. "Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 21-52, National Bureau of Economic Research, Inc.
    See citations under working paper version above.Sorry, no citations of chapters recorded.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 4 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.
  1. NEP-HEA: Health Economics (3) 2014-06-22 2017-12-03 2020-05-25
  2. NEP-COM: Industrial Competition (2) 2014-06-22 2020-05-25
  3. NEP-INO: Innovation (2) 2014-06-22 2020-05-25
  4. NEP-CNA: China (1) 2017-11-05
  5. NEP-CUL: Cultural Economics (1) 2017-11-05
  6. NEP-MKT: Marketing (1) 2017-11-05
  7. NEP-PPM: Project, Program and Portfolio Management (1) 2020-05-25
  8. NEP-TID: Technology and Industrial Dynamics (1) 2020-05-25

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Manuel Hermosilla should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.